Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

13.40 +0.15 (+1.13%)
Streaming Delayed Price Updated: 1:37 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
3 Chart Patterns That Cut Through The Market’s Chaos
There are endless ways of analyzing price data. But the truth is, I don’t use 90% of it. What I find most useful when analyzing stock charts is pattern recognition. Today, I’ll review three of the... 
Via Talk Markets
Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike
The U.S. 
Via Benzinga
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 guidance reaffirms strong growth outlook. 
Via Benzinga
These 10 Stocks Were S&P 500's Worst Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?
The S&P 500 enjoyed a strong year in 2021, the first year with Joe Biden in the White House. Not all stocks were up and past results could show sectors to avoid ahead of the 2024 election. 
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into Viatris's Recent Short Interest
Via Benzinga
Looking Into Viatris's Recent Short Interest
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. 
Via Benzinga
Exposures Product Safety
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron filed an appeal after a court's decision, which was issued under seal. 
Via Benzinga
EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching
CC Lagator of Options AI warns traders to expect increased volatility in the week after September's 'triple witching,' with over $5 trillion in options expiring and historical evidence of market... 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
3 Top Value Stocks to Buy Right Now
Value stocks offer potential for significant returns in today's overheated market. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Viatris reports Q2 revenue of $3.78 billion, with strong growth in Greater China and new product launches driving results. Adjusted EPS of $0.69 beats estimates, and the company raises its 2024 sales... 
Via Benzinga
Why Viatris Stock Is Jumping Today
Investors are applauding the healthcare company's improving growth story. 
Via The Motley Fool
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks arguably deserve more respect from investors. 
Via The Motley Fool
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your... 
Via Benzinga
S&P 500 Four Under Five
The S&P 500's strong first half, with gains exceeding 15%, has pushed its valuation even higher. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America.... 
Via Benzinga
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising uptick in unemployment claims prompting speculation over Federal Reserve... 
Via Benzinga
Topics Economy
Exposures Interest Rates
VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024
VTRS stock results show that Viatris met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
Via InvestorPlace
Steady Returns Ahead: 3 Dividend Stocks for Stable Income in Q2
Discover three top dividend stocks for stable income in April that combine sustainable returns and long-term growth. 
Via InvestorPlace
Is Viatris a Great Dividend Stock or Just a Value Trap?
Investors can collect a high yield with Viatris, but is it a risky payout to rely on? 
Via The Motley Fool
2 Dirt Cheap Dividend Stocks to Buy and Hold
These companies aren't popular on the market right now, but income investors will like them. 
Via The Motley Fool
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
From Scott+Scott Attorneys at Law and Hedin Hall LLP
Via Business Wire
Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?
Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last quarter of the year. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.